Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Novel Histamine Receptor Family Antagonists by Fragment Screening and Molecular Modelling

Mark Slack, Group Leader Cellular Assays, Evotec, speaking at MedChem Europe
Date Posted: Sunday, June 12, 2011
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic
A EUR 1.5 million BMBF grant will advance the H3 receptor antagonist programme through Phase I clinical studies.
Tuesday, April 27, 2010
Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties
Monday, November 09, 2009
Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
Evotec AG today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim.
Thursday, October 22, 2009
Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services
P&GP will access a wide range of discovery and preclinical expertise offered by Evotec, ranging from assay development, screening, medicinal and computational chemistry to scale-up and pharmaceutical manufacture.
Monday, July 25, 2005
Evotec OAI and Novartis Pharma AG Sign Lead Discovery Collaboration

Thursday, April 10, 2003
Evotec OAI collaboration with KeyNeurotek and IMTM

Wednesday, January 15, 2003
Evotec OAI Names President of Discovery Services

Tuesday, December 10, 2002
Evotec OAI Enters into Agreement With Venture Capital Firm

Thursday, November 14, 2002
Scientific News
Saccharin Shows Promise as Cancer Inhibitor
Researchers have found that the artificial sweetener can inhibit cancer cell growth.
Treating Canine Periodontal Disease
The class of compounds, designed to resolve inflammation, has potential to treat chronic disease in animals and humans.
‘Warhead’ Molecule Targets Deadly Bacteria
Boston college chemists target bacterial lipids to label deadly bacteria, spare healthy cells.
Garlic Could Aid Cystic Fibrosis Fight
A chemical in garlic kills bacteria that cause deadly infections in people with cystic fibrosis, University of Edinburgh research shows.
UGA Researchers Discover Potential Treatment for Drug-resistant Tuberculosis
Researchers have developed a new small molecule drug as a treatment against multi-drug resistant tuberculosis.
A Protein's Novel Role In Several Types Of Cancers Discovered
Stanford ChEM-H scientists are helping to develop a novel cancer therapy based on a new finding of a protein that inadvertently promotes cancer growth.
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
Grant will Help Develop More Powerful Disinfectants
$200,000 grant awarded to develop the next generation of antibacterial cleansers and disinfectants.
Artificially-intelligent Robot Scientist ‘Eve’ Could Boost Search for New Drugs
Eve, an artificially-intelligent ‘robot scientist’ could make drug discovery faster and much cheaper, say researchers writing in the Royal Society journal Interface.
Novogen Announces Important Discovery in Regenerative Medicine Program
A key proof-of-concept step to develop drugs capable of stimulating the function of brain tissue stem cells.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters